themiller schreef op 11 mrt 2019 om 11:33:
One in 20 women around the world suffers from preeclampsia during pregnancy. It causes a rise in blood pressure and kidney failure. It is one of the most common causes of death during pregnancy—for both the mother and the fetus.
There is currently no treatment and the only method doctors have to prevent it is early delivery.
“As long as the symptoms of the mother and fetus allow it, we can wait before initiating the birth,” says Ursula Quitterer, professor of molecular pharmacology at ETH Zurich.
Pharming Group (The Netherlands) filed a clinical trial application (CTA) with the European Medicines Agency in the Netherlands to initiate the clinical development of RUCONEST to treat and prevent pre-eclampsia. A similar filing has also been made in Australia.
When this trial goes well, it might be a big block buster for small pharmaceutical company Pharming.